DOCSLIB.ORG

Isobutene Formation from 3-Hydroxy-3-Methylbutyrate (3-HMB

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Isobutene Formation from 3-Hydroxy-3-Methylbutyrate (3-HMB Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2011 Isobutene formation from 3-hydroxy-3-methylbutyrate (3-HMB) by the Saccharomyces cerevisiae diphosphomevalonate decarboxylase (ScMDD) and directed enzyme evolution to improve enzyme function David Gogerty Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the Biochemistry, Biophysics, and Structural Biology Commons Recommended Citation Gogerty, David, "Isobutene formation from 3-hydroxy-3-methylbutyrate (3-HMB) by the Saccharomyces cerevisiae diphosphomevalonate decarboxylase (ScMDD) and directed enzyme evolution to improve enzyme function" (2011). Graduate Theses and Dissertations. 10353. https://lib.dr.iastate.edu/etd/10353 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Isobutene formation from 3-hydroxy-3-methylbutyrate (3-HMB) by the Saccharomyces cerevisiae diphosphomevalonate decarboxylase (Sc MDD) and directed enzyme evolution to improve enzyme function by David Gogerty A dissertation submitted to the graduate faculty in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Major: Biochemistry Program of Study Committee: Thomas A. Bobik, Major Professor Alan DiSpirito Basil Nikolau Donald Beitz Robert Brown Iowa State University Ames, Iowa 2011 Copyright © David Gogerty, 2011. All rights reserved. ii TABLE OF CONTENTS LIST OF FIGURES v LIST OF TABLES viii ACKNOWLEDGEMENTS ix ABSTRACT xi CHAPTER 1. General Introduction 1 I. Dependence on fossil fuels 1 II. Reducing our dependence through biofuels 3 III. Alternative biofuels 6 CHAPTER 2. Literature Review 8 Introduction 8 Alternative biofuels production 9 I. Butanol 9 II. Microbial hydrocarbon biosynthesis 17 III. Fatty acid biosynthesis 17 IV. Alkane biosynthesis 20 V. Ethylene 21 VI. Isobutene 22 Optimizing enzyme function 25 I. Rational design 25 II. Directed enzyme evolution 26 Mevalonate Decarboxylase 35 I. Mevalonate diphosphate decarboxylase (MDD) 35 II. Putative mevalonate monophosphate decarboxylase (MPD) 41 iii CHAPTER 3. Formation of Isobutene from 3-hydroxy-3-methylbutyrate by 44 Diphosphomevalonate Decarboxylase Abstract 44 Introduction 46 Materials and methods 47 Results 52 Discussion 60 CHAPTER 4. Mevalonate Growth Selection 66 Abstract 66 Introduction 67 Materials and methods 73 Results 77 Discussion 93 CHAPTER 5. Development of an Isobutene Biosensor 99 Abstract 99 Introduction 99 Materials and methods 102 Results 106 Discussion 114 iv CHAPTER 6. Synthetic Gene Shuffling to Expand Mevalonate Diphosphate 120 Decarboxylase Sequence Diversity Abstract 120 Introduction 120 Materials and methods 123 Results 124 Discussion 130 CHAPTER 7. Conclusion and Future Work 133 I. 3-HMB Synthesis 133 II. Search for mevalonate monophosphate decarboxylase 137 III. Additional increases in enzyme activity (biosensor) 139 IV. Directed evolution by mevalonate selection 141 ABBREVIATIONS 144 REFERENCES 145 v LIST OF FIGURES Figure 1. Native Clostridium butanol biosynthetic pathway. 12 Figure 2. Ehrlich pathway for alternative alcohol production. 15 Figure 3. Fatty acid biosynthetic pathway. 19 Figure 4. Ethylene biosynthetic pathways. 22 Figure 5. Isobutene biosynthesis from Rhodotorula minuta . 24 Figure 6. Mevalonate and methylerythritol phosphate pathways. 36 Figure 7. Mevalonate diphosphate decarboxylase reaction mechanism. 39 Figure 8. Reactions catalyzed by diphosphomevalonate decarboxylase (MDD). 52 Figure 9. GC-MS of isobutene produced by whole cells of Sc MDD variant R74H. 55 Figure 10. MS spectrum for isobutene produced by Sc MDD versus library standards. 56 Figure 11. SDS-PAGE analysis of His 6-Sc MDD purification. 57 Figure 12. Structural mapping of Sc MDD variants. 60 Figure 13. Possible pathway for the production of 3-HMB from glucose. 63 Figure 14. A step-wise approach to directed enzyme evolution. 70 Figure 15. Proposed isopentenol pathway. 71 Figure 16. Proposed isopentenol pathway with MEP and MVA pathways. 72 Figure 17. Isopentenol growth assay for isopentenyl phosphate kinase after 24 h. 79 vi Figure 18. Isopentenol growth assay for isopentenyl phosphate kinase after 103 h. 80 Figure 19. Chromosomal map of the lytB area of E. coli . 81 Figure 20. PCR confirmation of lytB knockout. 82 Figure 21. PCR confirmation of lytB knockout with IPK insertion. 84 Figure 22. GC-FID analysis of isopentenol production by ten mevalonate isolates. 88 Figure 23. Isopentenol-producing activity of MS-Sc-1 variant versus wild-type 89 (DG157). Figure 24. Detailed growth inhibition studies of fosmidomycin on revertant 91 phenotype. Figure 25. Broad study of growth inhibition by fosmidomycin on multiple revertants. 92 Figure 26. pTS biosensor fluorescence. 107 Figure 27. Fluorescence assay to determine the isobutene sensitivity of 107 the pTS biosensor. Figure 28. Luminescence assay to determine the E. coli -based biosensor’s 109 sensitivity to isobutene. Figure 29. pPROBE luminometer test. 109 Figure 30. β-galactosidase assay of an E. coli based pPROBE vector containing 111 the biosensor cassette (DG94). vii Figure 31. β-galactosidase assay of reengineered biosensor construct (DG112a). 112 Figure 32. β-galactosidase assay to determine substrate specificity of the 113 TbuT biosensor. Figure 33. ClustalW analysis of six homologs for synthetic gene shuffling. 125 Figure 34. Sc MDD amino acid sequence with residue labels. 126 Figure 35. Gel confirmation of the reconstitution of MDD from synthetic 129 gene shuffling. Figure 36. Potential 3-HMB biosynthetic pathways. 135 Figure 37. The two plasmid system for an E. coli based biosensor. 141 viii LIST OF TABLES Table 1. Select fuel molecules and their specs. 10 Table 2. Bacterial strains and plasmids used in chapter 3. 48 Table 3. Isobutene production by whole cells producing Sc MDD and variants. 54 Table 4. Isobutene formation by purified His 6-Sc MDD and His 6-Sc MDD2. 58 Table 5. Growth phenotype chart of lytB knockout mutants. 83 Table 6. Bacterial strains and plasmids used in chapter 4. 96 Table 7. Induction ratios for the E. coli based biosensors DG94 and DG112. 113 Table 8. Bacterial strains and plasmids used in chapter 5. 118 Table 9. Oligonucleotides designed for synthetic gene shuffling of Sc MDD. 128 ix ACKNOWLEDGEMENT I would like to thank my major professor Dr. Thomas Bobik, for the patient advice he has provided throughout my graduate work. His knowledge of the scientific tools needed to investigate our system as well as his keen interest in finding a solution to the problems we face was a constant source of help and encouragement thoughout. I look forward to applying the lessons that he guided me through in my future endeavors. I also would like to give a special thank you to all of my committee members who have given advice and guidance during my graduate work. Dr. Alan Dispirito, Dr. Basil Nikolau, Dr. Donald Bietz, and Dr. Robert Brown are all leaders of their fields and I feel very fortunate to have them as my committee members. Several colleagues have also given advice and support during my graduate work. Dr. Chenguang Fan, Dr. Shouqiang Cheng, Dr. Sharmistha Sinha, Dr. Huilin Zhu, and especially Christian Bartholomay have all been readily available for scientific conversations and advice. I would especially like to thank Stephanie Cline for her hard work on these projects, which would have been hard to complete to the extent that we did without her help. I would also like to acknowledge others who have worked in the lab, including Dr. Tracie Bierwagen, Flora Liu, Netra Agarkar, Casey Volker and Ji-An Chooi. Finally, I would like to say a big thank you to my family. My wife Jessica and son James have worked hard to give me the support to complete this work and I love x them very much. I would also like to thank my parents, Dan and Lana, as well as Jessica’s parents, Dan and Cheryl, for their indispensable help and support. xi ABSTRACT Dependence on petroleum for energy and petrochemical products has led to high energy costs, a polluted environment, the depletion of a finite resource (oil), and the reliance on hostile nations for our energy security. Biofuels promise to alleviate some or all of these issues but remain costly and inefficient to produce, and difficult to integrate into our existing transportation infrastructure. A renewable fuel molecule capable of replacing petroleum for our fuel and chemical industries is desired. Isobutene is an important commercial chemical used for the synthesis of butyl rubber, terephthalic acid, specialty chemicals, and a gasoline performance additive known as alkylate. Currently, isobutene is produced from petroleum and hence is nonrenewable. Here we report that the Saccharomyces cerevisiae mevalonate diphosphate decarboxylase ( Sc MDD) can convert 3-hydroxy-3-methylbutyrate (3-HMB) to isobutene. Whole cells of Escherichia coli producing Sc MDD formed isobutene from 3-HMB at a rate of 154 pmol h -1 g cells -1. His 6-Sc MDD was purified by nickel affinity chromatography and shown to produce isobutene from 3-HMB at a rate of 1.33 pmol min -1 mg -1 protein. In contrast, no isobutene was detected from control cells lacking Sc MDD, and controls showed that both His 6-Sc MDD and 3-HMB were required for detectable isobutene formation in enzyme assays. Sc MDD was subjected to error-prone PCR and 2 improved variants were characterized, Sc MDD1 (I145F) and Sc MDD2 (R74H). Whole cells of E. coli producing Sc MDD1 and Sc MDD2 produced isobutene from 3-HMB at rates of 3000 and 5888 pmol -1 -1 h g cells which are 19- and 38-fold increases compared to cells producing His 6- Sc MDD. Although Sc MDD was shown to be amenable to manipulation in order to xii increase its activity on 3-HMB, we estimate that a 10 6 fold increase in activity is needed for commercial application.
Load more

Recommended publications
  • Mgcl2 and Kcl Recovery from Brine Wastewater
    University of Pennsylvania ScholarlyCommons Department of Chemical & Biomolecular Senior Design Reports (CBE) Engineering 4-2016 MgCl2 and KCl Recovery from Brine Wastewater Arthur M. Rempel University of Pennsylvania, [email protected] Kyra G. Berger University of Pennsylvania, [email protected] Elyssa A. Gensib University of Pennsylvania, [email protected] Aspen N. Walker University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/cbe_sdr Part of the Biochemical and Biomolecular Engineering Commons Rempel, Arthur M.; Berger, Kyra G.; Gensib, Elyssa A.; and Walker, Aspen N., "MgCl2 and KCl Recovery from Brine Wastewater" (2016). Senior Design Reports (CBE). 82. https://repository.upenn.edu/cbe_sdr/82 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/cbe_sdr/82 For more information, please contact [email protected]. MgCl2 and KCl Recovery from Brine Wastewater Abstract This project’s aim was to design an improved brine wastewater treatment system for desalination facilities. While a multitude of methods exist to do so, General Electric (GE)’s brine concentrator is leading the market by providing a method that not only treats the brine waste, but also recovers anywhere from 60- 94% of the water from the feed. However, their brine concentrator is relatively inefficient omfr both a financial and energetic perspective; our goal was to develop a system to match their results, while limiting costs and energy usage as best possible. We subsequently designed a system (referred to from here on out as the ‘MgCl2 Separation Unit’) to accomplish the aforementioned objectives. In addition to recovering pure water from concentrated brine, our process also recovers high purity MgCl2 and KCl crystals that are later sold to alleviate the overall process costs.
    [Show full text]
  • Magnesium Magic by Terri Saunders
    Magnesium Magic By Terri Saunders Minerals provide the physical elements that comprise life and fats and amino acids and create the physical structure of the of all the minerals on Earth, none are as essential to life as the body based on the genetic blueprint provided by the RNA and element magnesium. The Chinese word for magnesium is DNA. “mei” meaning beautiful mineral, and traditional Chinese Magnesium does an intricate dance with calcium to regulate healers consider it to be paramount in healing properties due to significant body functions. Magnesium plays a critical role in its ability to prevent and cure disease, maintain health and the function of the nervous system by acting as a gatekeeper for promote longevity. Dr. Jerry Aikawa refers to magnesium as calcium, permitting just enough calcium to enter a nerve cell to the most important mineral to man and all other living allow electrical transmission along the nerves to and from the organisms. brain, then forcing the calcium back out again. This exchange Deposits of magnesium were discovered by man near the provides the electrical spark that powers our thoughts and ancient Greek city of Magnesia. Magnesium sulfate (Epsom emotions. While calcium contracts muscle fibers, magnesium salts) was employed then as a laxative and still is today. relaxes muscles. When there is too much calcium and Magnesium was also used to heal a variety of conditions insufficient magnesium inside a cell the muscles stay contracted including heartburn, depression, vertigo, ulcers, kidney stones, resulting in spasms, twitches and even convulsions. jaundice, gout and worms. In the last 40 years, over 1,000 There are many smooth muscles in the body that can over- laboratory studies have been conducted revealing at least a contract and go into spasm when magnesium is deficient.
    [Show full text]
  • Some Drugs Are Excluded from Medicare Part D, but Are Covered by Your Medicaid Benefits Under the Healthpartners® MSHO Plan (HMO)
    Some drugs are excluded from Medicare Part D, but are covered by your Medicaid benefits under the HealthPartners® MSHO Plan (HMO). These drugs include some over‐the‐counter (OTC) items, vitamins, and cough and cold medicines. If covered, these drugs will have no copay and will not count toward your total drug cost. For questions, please call Member Services at 952‐967‐7029 or 1‐888‐820‐4285. TTY members should call 952‐883‐6060 or 1‐800‐443‐0156. From October 1 through February 14, we take calls from 8 a.m. to 8 p.m., seven days a week. You’ll speak with a representative. From February 15 to September 30, call us 8 a.m. to 8 p.m. Monday through Friday to speak with a representative. On Saturdays, Sundays and holidays, you can leave a message and we’ll get back to you within one business day. Drug Description Strength 3 DAY VAGINAL 4% 5‐HYDROXYTRYPTOPHAN 50 MG ABSORBASE ACETAMINOPHEN 500 MG ACETAMINOPHEN 120MG ACETAMINOPHEN 325 MG ACETAMINOPHEN 650MG ACETAMINOPHEN 80 MG ACETAMINOPHEN 650 MG ACETAMINOPHEN 160 MG/5ML ACETAMINOPHEN 500 MG/5ML ACETAMINOPHEN 160 MG/5ML ACETAMINOPHEN 500MG/15ML ACETAMINOPHEN 100 MG/ML ACETAMINOPHEN 500 MG ACETAMINOPHEN 325 MG ACETAMINOPHEN 500 MG ACETAMINOPHEN 80 MG ACETAMINOPHEN 100.00% ACETAMINOPHEN 80 MG ACETAMINOPHEN 160 MG ACETAMINOPHEN 80MG/0.8ML ACETAMINOPHEN‐BUTALBITAL 50MG‐325MG ACNE CLEANSING PADS 2% ACNE TREATMENT,EXTRA STRENGTH 10% ACT ANTI‐CAVITY MOUTH RINSE 0.05% Updated 12/01/2012 ACTICAL ACTIDOSE‐AQUA 50G/240ML ACTIDOSE‐AQUA 15G/72ML ACTIDOSE‐AQUA 25G/120ML ACTIVATED CHARCOAL 25 G ADEKS 7.5 MG
    [Show full text]
  • Effect of Leucine on Intestinal Absorption of Tryptophan in Rats
    Downloaded from https://doi.org/10.1079/BJN19850155 British Journal of Nutrition (1985), 54, 695-703 695 https://www.cambridge.org/core Effect of leucine on intestinal absorption of tryptophan in rats BY CHISAE UMEZAWA, YUKO MAEDA, KANJI HABA, MARIKO SHIN AND KEIJI SANO School of Pharmacy, Kobe-Gakuin University, Nishi-ku, Kobe 673, Japan (Received I7 May 1985 - Accepted 24 June 1985) . IP address: 1. To elucidate the causal relation between leucine and the lowering of hepatic NAD content of rats fed on a leucine-excessive diet (Yamada et aZ. 1979), the effect of leucine on intestinal absorption of tryptophan was 170.106.35.93 investigated. 2. Co-administration of [3H]tryptophan and leucine, with leucine at ten times the level of tryptophan, delayed absorption of L-[side chain 2,3-3H]tryptophan from the digestive tract and incorporation of [3H]tryptophan into portal blood, the liver and a protein fraction of the liver. After 120 min, more than 95% of tryptophan was absorbed whether [3H]tryptophan was administered with or without leucine. , on 3. Co-administration of a mixture of ten essential amino acids, in proportions simulating casein, with 02 Oct 2021 at 04:49:27 [3H]tryptophan markedly delayed absorption of tryptophan from the digestive tract. The addition of supplementary leucine to the amino acid mixture, however, caused no further delay. 4. In rats prefed a leucine-excessive diet for 1 week [3H]tryptophan was absorbed at the same rate as in rats fed on a control diet. 5. The results indicate that competition between tryptophan and leucine for intestinal absorption did not cause lowering of hepatic NAD.
    [Show full text]
  • Electrochemical Studies of Dl-Leucine, L-Proline and L
    ELECTROCHEMICAL STUDIES OF DL -LEUCINE, 60 L-PROLINE AND L-TRYPTOPHAN AND THEIR INTERACTION WITH COPPER AND IRON 30 c b A) M. A. Jabbar, R. J. Mannan, S. Salauddin and B. µ a Rashid 0 Department of Chemistry, University of Dhaka, ( Current Dhaka-1000, Bangladesh -30 Introduction -60 In vitro study of the charge transfer reactions coupled -800 -400 0 400 800 with chemical reactions can give important indication of Potential vs. Ag/AgCl (mV) about actual biological processes occurring in human Fig.1. Comparison of the cyclic voltammogram of system. Understanding of such charge-transfer 5.0mM (a) DL -Leucine, (b) Cu-DL -Leucine ion and mechanism will help to determine the effectiveness of (c) [Fe-DL -Leucine] in 0.1M KCl solution at a Pt- nutrition, metabolism and treatment of various biological button electrode. Scan rates 50 mV/s. disorders. In the previous research, the redox behaviour of 40 various amino acids and biochemically important compounds and their charge transfer reaction and their b interaction of metal ions were studied [1,2]. In the present 20 ) a c research, the redox behavior and the charge transfer µΑ kinetics of DL -Leucine, L-Proline and L-Tryptophan in 0 the presence and absence of copper and iron will be investigated. Current ( -20 Experimental A computerized electrochemistry system developed by -40 -800 -400 0 400 800 Advanced Analytics, Virginia, USA, (Model-2040) Potential vs. Ag/AgCl (mV) consisting of three electrodes micro-cell with a saturated Ag/AgCl reference, a Pt-wire auxiliary and a pretreated Fig.2 . Comparison of the cyclic voltammogram of Pt-button working electrode is employed to investigate 5.0mM (a) L-Proline, (b) Cu-L-Proline and (c) Fe-L- Proline in 0.1M KCl solution at a Pt-button different amino acids and metal-amino acid systems.
    [Show full text]
  • Physicochemical Properties of Organic Medicinal Agents
    Principles of Drug Action 1, Spring 2005, Esters ESTERS AND RELATED CARBOXYLIC ACID DERIVATIVES Jack DeRuiter I. Structure and Preparation Esters are derivatives of carboxylic acids that arise via replacement of the hydroxyl (OH) portion of the acid COOH function with an "ether" moiety (-OR): O O H C C O C O Acid Ester Note that replacement of the acid OH group with an "ether" moiety removes the acidic function from the parent structure (acid) resulting in the formation of non-acidic (neutral, but somewhat polar) compounds (esters). Esters can be sub-classified based on their general structure as aliphatic, aromatic or cyclic (called "lactones") as illustrated by the examples below: O O CH2CH3 CH2CH3 O CH3 O O O Aliphatic Ester Aromatic Ester Cyclic Ester (Lactone) A variety of methods have been developed for the preparation of esters. Most of these methods involve reaction of an alcohol with an "activated carboxylic acid" compound (i.e. acid chloride): O O H C C X OC C O X- Ester "Activated" acid (X=Cl) Alcohol (Electrophile) (Nucleophile) The ester functionality does not introduce a center of asymmetry and thus optical and geometric isomerism does not result from the presence of this functional group. The ester functionality (the carbonyl and ether oxygen) is composed of an sp2 hybridized carbon so it cannot be chiral, and since there is free rotation about the ether bond geometric isomerism also is not possible at the sp2 center. 1 Principles of Drug Action 1, Spring 2005, Esters II. Solubility of Esters Esters contain carbonyl (C=O) and ether (O-C) dipoles arising from covalent bonding between electronegative oxygen atoms and electronically neutral carbon atoms.
    [Show full text]
  • Article in Press
    ARTICLE IN PRESS Journal of Light Metals xxx ,2001) xxx±xxx www.elsevier.com/locate/ligandmet 2 A thermochemical analysis of the production of anhydrous MgCl2 a b, 3 Georges J. Kipouros , Donald R. Sadoway * 4 a Department of Mining and Metallurgical Engineering, Dalhousie University, 1360 Barrington Street, Halifax, Nova Scotia, Canada B3J 2X4 5 b Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139-4307, USA 6 Abstract 7 The electrolytic production of magnesium requires high-purity, anhydrous magnesium chloride which has a high anity for 8 water and is found in nature as a plurality of hydrates ,MgCl2 Á nH2O, n 1, 2, 4, 6, 8, 12). Their dehydration is nontrivial and can 9 be accompanied by hydrolysis leading to the production of undesirable oxycompounds of magnesium.PROOF Through an analysis of the 10 relevant thermochemistry this paper indicates howto prevent hydrolysis and make electrolytic-grade, anhydrous MgCl 2. Ó 2001 11 Published by Elsevier Science Ltd. 12 Keywords: Magnesium; Hydrolysis; Dehydration; Thermochemistry 13 1. Introduction 2. Background 38 14 With a density of 1:74 g=cm3 magnesium is 4.5 times A cubic kilometer of seawater contains approxi- 39 15 lighter than steel and 1.6 times lighter than aluminum mately a million tones of magnesium, more than has 40 16 [1]. The mechanical properties of magnesium castings ever been produced in one year by all the magnesium 41 17 make them competitive with aluminum castings. When plants in the world. Furthermore, seawater contains 42 18 hot worked, magnesium is the easiest to deep draw of only 3.7% of the total magnesium present in the earth's 43 19 the common metals and requires the least energy to crust.
    [Show full text]
  • 33 34 35 Lipid Synthesis Laptop
    BI/CH 422/622 Liver cytosol ANABOLISM OUTLINE: Photosynthesis Carbohydrate Biosynthesis in Animals Biosynthesis of Fatty Acids and Lipids Fatty Acids Triacylglycerides contrasts Membrane lipids location & transport Glycerophospholipids Synthesis Sphingolipids acetyl-CoA carboxylase Isoprene lipids: fatty acid synthase Ketone Bodies ACP priming 4 steps Cholesterol Control of fatty acid metabolism isoprene synth. ACC Joining Reciprocal control of b-ox Cholesterol Synth. Diversification of fatty acids Fates Eicosanoids Cholesterol esters Bile acids Prostaglandins,Thromboxanes, Steroid Hormones and Leukotrienes Metabolism & transport Control ANABOLISM II: Biosynthesis of Fatty Acids & Lipids Lipid Fat Biosynthesis Catabolism Fatty Acid Fatty Acid Synthesis Degradation Ketone body Utilization Isoprene Biosynthesis 1 Cholesterol and Steroid Biosynthesis mevalonate kinase Mevalonate to Activated Isoprenes • Two phosphates are transferred stepwise from ATP to mevalonate. • A third phosphate from ATP is added at the hydroxyl, followed by decarboxylation and elimination catalyzed by pyrophospho- mevalonate decarboxylase creates a pyrophosphorylated 5-C product: D3-isopentyl pyrophosphate (IPP) (isoprene). • Isomerization to a second isoprene dimethylallylpyrophosphate (DMAPP) gives two activated isoprene IPP compounds that act as precursors for D3-isopentyl pyrophosphate Isopentyl-D-pyrophosphate all of the other lipids in this class isomerase DMAPP Cholesterol and Steroid Biosynthesis mevalonate kinase Mevalonate to Activated Isoprenes • Two phosphates
    [Show full text]
  • Amino Acid Chemistry
    Handout 4 Amino Acid and Protein Chemistry ANSC 619 PHYSIOLOGICAL CHEMISTRY OF LIVESTOCK SPECIES Amino Acid Chemistry I. Chemistry of amino acids A. General amino acid structure + HN3- 1. All amino acids are carboxylic acids, i.e., they have a –COOH group at the #1 carbon. 2. All amino acids contain an amino group at the #2 carbon (may amino acids have a second amino group). 3. All amino acids are zwitterions – they contain both positive and negative charges at physiological pH. II. Essential and nonessential amino acids A. Nonessential amino acids: can make the carbon skeleton 1. From glycolysis. 2. From the TCA cycle. B. Nonessential if it can be made from an essential amino acid. 1. Amino acid "sparing". 2. May still be essential under some conditions. C. Essential amino acids 1. Branched chain amino acids (isoleucine, leucine and valine) 2. Lysine 3. Methionine 4. Phenyalanine 5. Threonine 6. Tryptophan 1 Handout 4 Amino Acid and Protein Chemistry D. Essential during rapid growth or for optimal health 1. Arginine 2. Histidine E. Nonessential amino acids 1. Alanine (from pyruvate) 2. Aspartate, asparagine (from oxaloacetate) 3. Cysteine (from serine and methionine) 4. Glutamate, glutamine (from α-ketoglutarate) 5. Glycine (from serine) 6. Proline (from glutamate) 7. Serine (from 3-phosphoglycerate) 8. Tyrosine (from phenylalanine) E. Nonessential and not required for protein synthesis 1. Hydroxyproline (made postranslationally from proline) 2. Hydroxylysine (made postranslationally from lysine) III. Acidic, basic, polar, and hydrophobic amino acids A. Acidic amino acids: amino acids that can donate a hydrogen ion (proton) and thereby decrease pH in an aqueous solution 1.
    [Show full text]
  • WO 2009/005519 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 8 January 2009 (08.01.2009) WO 2009/005519 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/19 (2006.01) A61K 31/185 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/20 (2006.01) A61K 31/225 (2006.01) AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, (21) International Application Number: ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, PCT/US2007/072499 IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, (22) International Filing Date: 29 June 2007 (29.06.2007) MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, (25) Filing Language: English TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (26) Publication Language: English (71) Applicant (for all designated States except US): AC- (84) Designated States (unless otherwise indicated, for every CERA, INC. [US/US]; 380 Interlocken Crescent, Suite kind of regional protection available): ARIPO (BW, GH, 780, Broomfield, CO 80021 (US). GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), (72) Inventor; and European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, (75) Inventor/Applicant (for US only): HENDERSON, FR, GB, GR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, PL, Samuel, T.
    [Show full text]
  • Magnesium Chloride | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Magnesium Chloride This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Chloromag [DSC]; Mag-SR Plus Calcium [OTC]; Magdelay [OTC] [DSC]; Nu-Mag [OTC]; Slow Magnesium/Calcium [OTC]; Slow-Mag [OTC]; SlowMag Mg Muscle/Heart [OTC] What is this drug used for? It is used to treat or prevent low magnesium levels. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have any of these health problems: Heart disease or kidney disease. This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. Magnesium Chloride 1/6 What are some things I need to know or do while I take this drug? All products: Tell all of your health care providers that you take this drug. This includes your doctors, nurses, pharmacists, and dentists. Have blood work checked as you have been told by the doctor.
    [Show full text]
  • Nucleotide Base Coding and Am1ino Acid Replacemients in Proteins* by Emil L
    VOL. 48, 1962 BIOCHEMISTRY: E. L. SAIITH 677 18 Britten, R. J., and R. B. Roberts, Science, 131, 32 (1960). '9 Crestfield, A. M., K. C. Smith, and F. WV. Allen, J. Biol. Chem., 216, 185 (1955). 20 Gamow, G., Nature, 173, 318 (1954). 21 Brenner, S., these PROCEEDINGS, 43, 687 (1957). 22 Nirenberg, M. WV., J. H. Matthaei, and 0. WV. Jones, unpublished data. 23 Crick, F. H. C., L. Barnett, S. Brenner, and R. J. Watts-Tobin, Nature, 192, 1227 (1961). 24 Levene, P. A., and R. S. Tipson, J. Biol. Ch-nn., 111, 313 (1935). 25 Gierer, A., and K. W. Mundry, Nature, 182, 1437 (1958). 2' Tsugita, A., and H. Fraenkel-Conrat, J. Mllot. Biol., in press. 27 Tsugita, A., and H. Fraenkel-Conrat, personal communication. 28 Wittmann, H. G., Naturwissenschaften, 48, 729 (1961). 29 Freese, E., in Structure and Function of Genetic Elements, Brookhaven Symposia in Biology, no. 12 (1959), p. 63. NUCLEOTIDE BASE CODING AND AM1INO ACID REPLACEMIENTS IN PROTEINS* BY EMIL L. SMITHt LABORATORY FOR STUDY OF HEREDITARY AND METABOLIC DISORDERS AND THE DEPARTMENTS OF BIOLOGICAL CHEMISTRY AND MEDICINE, UNIVERSITY OF UTAH COLLEGE OF MEDICINE Communicated by Severo Ochoa, February 14, 1962 The problem of which bases of messenger or template RNA' specify the coding of amino acids in proteins has been largely elucidated by the use of synthetic polyri- bonucleotides.2-7 For these triplet nucleotide compositions (Table 1), it is of in- terest to examine some of the presently known cases of amino acid substitutions in polypeptides or proteins of known structure.
    [Show full text]